Chung DL

ORCID: 0000-0003-2425-8586 · 1 paper in corpus
2025
International journal of molecular sciences ·doi:10.3390/ijms26104697

The management of nasopharyngeal cancer (NPC) is rapidly evolving, with immune checkpoint inhibitors emerging as a prominent treatment approach. However, drug development targeting specific molecular and cellular abnormalities in NPC has sl…